Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present at the 44th Annual J.P.
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 12:00 p.m. PT / 3:00 p.m. ET in San Francisco.
The company said the live presentation and replay will be available on its investor Events page at https://investors.lexpharma.com/.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LXRX
In the Jan 7 session, LXRX gained 2.63%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference edition
- 44th
- 44th Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 15
- Scheduled conference presentation date
- Presentation time PT
- 12:00 p.m. PT
- Scheduled presentation time at conference
- Presentation time ET
- 3:00 p.m. ET
- Corresponding Eastern Time for presentation
Historical Context
-
Publication of ACSL5 preclinical data supporting LX9851’s scientific rationale.
-
Upcoming sotagliflozin adipose distribution data presentation at CVCT 2025.
-
December investor conference appearances with webcast access for investors.
-
Jefferies London Healthcare Conference fireside chat announcement.
-
Q3 2025 financial results and broad pipeline progress, including LX9851 and SONATA-HCM.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco.
The live event and replay of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.